Charles A. Flentge

1.0k citations

14 papers · 738 indexed · h-index 9

Co-authors: Dale J. Kempf Kennan C. Marsh Sudthida Vasavanonda Edith McDonald Jon F. Denissen Warren M. Kati Akhteruzzaman Molla Chen Zhao
Topics: HIV/AIDS drug development and treatment (12 papers)HIV Research and Treatment (5 papers)Hepatitis C virus research (5 papers)
Cited by: Virology Infectious Diseases Hepatology
Journals: Proceedings of the National Academy of Sciences Journal of Medicinal Chemistry Journal of Hepatology
Partner nations: United States Poland United Kingdom

In The Last Decade

Charles A. Flentge

14 papers receiving 716 citations

Peers

Countries citing papers authored by Charles A. Flentge

Since Specialization

Citations

This map shows the geographic impact of Charles A. Flentge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles A. Flentge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles A. Flentge more than expected).

Fields of papers citing papers by Charles A. Flentge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles A. Flentge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles A. Flentge. The network helps show where Charles A. Flentge may publish in the future.

Co-authorship network of co-authors of Charles A. Flentge

This figure shows the co-authorship network connecting the top 25 collaborators of Charles A. Flentge. A scholar is included among the top collaborators of Charles A. Flentge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles A. Flentge. Charles A. Flentge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Discovery of fluorobenzimidazole HCV NS5A inhibitors 2016 ·Bioorganic & Medicinal Chemistry Letters ·John T. Randolph,Charles A. Flentge,(unknown),Todd W. Rockway,(unknown),Lissa T.J. Nelson,Douglas K. Hutchinson,Rubina Mondal,(unknown),Thomas Reisch,Tatyana Dekhtyar,Preethi Krishnan,Edward Tam,DeAnne Stolarik,David W. A. Beno,Rolf Wagner,Clarence J. Maring,Warren M. Kati	4
2	Identification of aryl dihydrouracil derivatives as palm initiation site inhibitors of HCV NS5B polymerase 2012 ·Bioorganic & Medicinal Chemistry Letters ·Yaya Liu,(unknown),(unknown),Charles A. Flentge,Douglas K. Hutchinson,Darold L. Madigan,John T. Randolph,Rolf Wagner,Clarence J. Maring,Warren M. Kati,Akhteruzzaman Molla	20
3	Hepatitis C NS5B polymerase inhibitors: Functional equivalents for the benzothiadiazine moiety 2011 ·Bioorganic & Medicinal Chemistry Letters ·Douglas K. Hutchinson,Charles A. Flentge,(unknown),Rolf Wagner,Clarence J. Maring,Warren M. Kati,Yaya Liu,Sherie Masse,Tim Middleton,Hongmei Mo,Debra Montgomery,(unknown),Gennadiy Koev,David W. A. Beno,Kent D. Stewart,Vincent S. Stoll,Akhteruzzaman Molla,Dale J. Kempf	7
4	Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs 2009 ·Bioorganic & Medicinal Chemistry Letters ·Charles A. Flentge,John T. Randolph,Peggy Huang,Larry L. Klein,Kennan C. Marsh,John E. Harlan,Dale J. Kempf	9
5	Synthesis and Biological Characterization of B-Ring Amino Analogues of Potent Benzothiadiazine Hepatitis C Virus Polymerase Inhibitors 2009 ·Journal of Medicinal Chemistry ·John T. Randolph,Charles A. Flentge,Peggy Huang,Douglas K. Hutchinson,Larry L. Klein,Hock Ben Lim,Rubina Mondal,Thomas Reisch,Debra Montgomery,(unknown),Sherie Masse,Lisa E. Hernandez,Rodger F. Henry,Yaya Liu,Gennadiy Koev,Warren M. Kati,Kent D. Stewart,David W. A. Beno,Akhteruzzaman Molla,Dale J. Kempf	34
6	953 CHARACTERIZATION OF RESISTANCE MUTATIONS SELECTED IN VITRO BY THE NON-NUCLEOSIDE HCV POLYMERASE INHIBITORS ABT-333 AND ABT-072 2009 ·Journal of Hepatology ·(unknown),Rubina Mondal,Jill Beyer,Thomas Reisch,Sherie Masse,Warren M. Kati,David Hutchinson,Charles A. Flentge,John T. Randolph,(unknown),(unknown),Renaud Wagner,Pengke Yan,Tsung‐I Lin,Clarence J. Maring,Akhteruzzaman Molla	8
7	955 PRECLINICAL POTENCY, PHARMACOKINETIC AND ADME CHARACTERIZATION OF ABT-333, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR 2009 ·Journal of Hepatology ·Clarence J. Maring,Renaud Wagner,David Hutchinson,Charles A. Flentge,Warren M. Kati,(unknown),(unknown),David W. A. Beno,Jiajia Shen,Yau Yi Lau,Yonggang Gao,(unknown),Sujata Vaidyanathan,(unknown),J. Beyer,Rubina Mondal,(unknown)	15
8	Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors 2006 ·Bioorganic & Medicinal Chemistry ·John T. Randolph,Peggy Huang,(unknown),David A. DeGoey,Larry L. Klein,Clinton M. Yeung,Charles A. Flentge,(unknown),Chen Zhao,Tatyana Dekhtyar,Hongmei Mo,(unknown),Warren M. Kati,Kennan C. Marsh,Akhteruzzaman Molla,Dale J. Kempf	10
9	Oximinoarylsulfonamides as potent HIV protease inhibitors 2005 ·Bioorganic & Medicinal Chemistry Letters ·Clinton M. Yeung,Larry L. Klein,Charles A. Flentge,John T. Randolph,Chen Zhao,(unknown),Tatyana Dekhtyar,Vincent S. Stoll,Dale J. Kempf	27
10	Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy 1998 ·Journal of Medicinal Chemistry ·Dale J. Kempf,Hing L. Sham,Kennan C. Marsh,Charles A. Flentge,David A. Betebenner,(unknown),Edith McDonald,Sudthida Vasavanonda,Ayda Saldivar,Norman E. Wideburg,Warren M. Kati,(unknown),Chen Zhao,(unknown),(unknown),Akhteruzzaman Molla,Jacob J. Plattner,Daniel W. Norbeck	145
11	Lack of stereospecificity in the binding of the P2 amino acid of ritonavir to HIV protease 1997 ·Bioorganic & Medicinal Chemistry Letters ·Dale J. Kempf,Akhteruzzaman Molla,Kennan C. Marsh,Chulyong Park,A. David Rodrigues,Marina Korneyeva,Sudthida Vasavanonda,Edith McDonald,Charles A. Flentge,Steven W. Muchmore,Norman E. Wideburg,Ayda Saldivar,(unknown),Warren M. Kati,Kent D. Stewart,Daniel W. Norbeck	4
12	Evaluation of substituted benzamides as P2 ligands for symmetry-based inhibitors of HIV protease 1995 ·Bioorganic & Medicinal Chemistry Letters ·Dale J. Kempf,Charles A. Flentge,Norman E. Wideburg,Ayda Saldivar,Sudthida Vasavanonda,Daniel W. Norbeck	7
13	ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. 1995 ·Proceedings of the National Academy of Sciences ·Dale J. Kempf,Kennan C. Marsh,Jon F. Denissen,Edith McDonald,Sudthida Vasavanonda,Charles A. Flentge,(unknown),(unknown),(unknown),(unknown)	446
14	Symmetry-Based Inhibitors of HIV Protease with Rigid P2 Amino Acid Mimics 1994 ·Protein and Peptide Letters ·Dale J. Kempf,Kent D. Stewart,(unknown),Charles A. Flentge,Norman E. Wideburg,Ayda Saldivar,Sudthida Vasavanonda,Daniel W. Norbeck	2

About Charles A. Flentge

Charles A. Flentge is a scholar working on Virology, Infectious Diseases and Hepatology, having authored 14 papers that have together received 738 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (5 papers) and Hepatitis C virus research (5 papers). The work is most often cited by research in Virology (303 citations), Infectious Diseases (445 citations) and Hepatology (80 citations). Charles A. Flentge has collaborated with scholars based in United States, Poland and United Kingdom. Frequent co-authors include Dale J. Kempf, Kennan C. Marsh, Sudthida Vasavanonda, Edith McDonald, Jon F. Denissen, Warren M. Kati, Akhteruzzaman Molla, Chen Zhao, Ayda Saldivar and Norman E. Wideburg. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Medicinal Chemistry and Journal of Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact